loading page

Sickle Cell Disease and COVID-19: Susceptibility and Severity
  • Zohreh Rahimi,
  • Babak Sayad
Zohreh Rahimi
Kermanshah University of Medical Sciences
Author Profile
Babak Sayad
Kermanshah University of Medical Sciences
Author Profile

Abstract

Sickle cell disease (SCD) patients are immunocompromised with multiple comorbidities and a hypercoagulation state. On the other hand COVID-19 is associated with cytokine storm and hypercoagulability. To find the susceptibility and the clinical course of COVID-19 in SCD patients we surveyed related published papers from USA, Europe, Middle East, few African patients and international SCD registry. The COVID-19 presentation was mild in children and moderate in many SCD adults. To explain these findings, possible benefits of high HbF level, and hydroxyurea therapy could be considered. The obtained results should be interpreted considering low cases from sub-Saharan people, younger age of SCD patients compared to general population, a bias toward registry of more severe form of the disease, the influence of preexisting comorbidities with multisystem organ damage in exacerbation of the COVID-19 and the fatality rate in SCD patients and the role of health socio-economic determinants.

Peer review status:ACCEPTED

26 Nov 2020Submitted to Pediatric Blood & Cancer
26 Nov 2020Submission Checks Completed
26 Nov 2020Assigned to Editor
29 Nov 2020Reviewer(s) Assigned
25 Dec 2020Review(s) Completed, Editorial Evaluation Pending
26 Dec 2020Editorial Decision: Revise Major
26 Jan 2021Assigned to Editor
26 Jan 2021Submission Checks Completed
26 Jan 20211st Revision Received
29 Jan 2021Reviewer(s) Assigned
19 Feb 2021Review(s) Completed, Editorial Evaluation Pending
19 Feb 2021Editorial Decision: Revise Minor
26 Feb 20212nd Revision Received
26 Feb 2021Submission Checks Completed
26 Feb 2021Assigned to Editor
28 Feb 2021Reviewer(s) Assigned
04 Apr 2021Review(s) Completed, Editorial Evaluation Pending
06 Apr 2021Editorial Decision: Revise Minor
06 Apr 2021Submission Checks Completed
06 Apr 20213rd Revision Received
06 Apr 2021Assigned to Editor
08 Apr 2021Review(s) Completed, Editorial Evaluation Pending
08 Apr 2021Editorial Decision: Accept